MIRA
INFORM REPORT
|
Report Date : |
07.01.2008 |
IDENTIFICATION
DETAILS
|
Name : |
SC CONSULTING INC |
|
|
|
|
Registered Office : |
Tokyo Sankei Bldg 27F, 1-7-2 Ohtemachi Chiyodaku Tokyo 100-0004 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Date of Incorporation : |
Apr 2006 |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki Kaisha) |
|
|
|
|
Line of Business : |
Technology transfer business |
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Maximum Credit Limit : |
Yen 1 million |
|
|
|
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
name
SC CONSULTING INC
REGD NAME
S C Consulting KK
MAIN OFFICE
Tokyo Sankei Bldg 27F, 1-7-2 Ohtemachi Chiyodaku Tokyo 100-0004 JAPAN
Tel : 03-3242-6358
Fax : 03-3242-6359
URL : http://www.sc-consultinc.com/
E-Mail address: info@sc-consultinc.com
* Registered at: 8 Ichibancho Chiyodaku
Tokyo
ACTIVITIES
Technology transfer business
BRANCHES
Nil
OFFICER(S)
JUNZO ISHIGURO, PRES
Atsuo Nakanishi, dir
Mark J Treherne PhD, adviser
Yen Amount: In
million Yen, unless otherwise stated
SUMMARY
FINANCES UNDETD A/SALES Yen 50 M*
PAYMENTS REGULAR CAPITAL Yen 100 M
TREND UNDETD WORTH Yen 100 M
STARTED 2006 EMPLOYES 5
* Estimated figures
only.
COMMENT
TECHNOLOGY TRANSFER BUSINESS.
FINANCIAL SITUATION UNDETERMINED DUE TO THE RECENT INCEPTION BUT SHOULD
BE GOOD FOR MODERATE BUSINESS ENGAGEMENTS.
MAX CREDIT LIMIT: YEN 1 MILLION, 30 DAYS, RECOMMENDING SECURED
TERMS ON NEW TRANSACTIONS. FINANCIALS
ARE NOT DISCLOSED.
HIGHLIGHTS
The subject company was established originally in 2003 on the basis of a technology transfer business division separated from Sosei Group Corp, pharmaceutical mfr, Tokyo, as Sosei Consulting KK. In Apr 2006, spun off from the Sosei Group and became independent, renamed SC Consulting Inc. This is a technology transfer business company in pharmaceuticals & biotechnology industries, representing over 10 Western companies in Japan.
FINANCIAL INFORMATION
Financials are not disclosed.
The sales volume for the initial accounting term ending Mar
2007 fiscal term is estimated amounted to Yen 50 million, on a break-even
profit basis.
For the current term ending Mar 2008 the net profit is projected
at Yen 10 million, on an estimated twofold rise in turnover, to Yen 100
million. Some reports Yen 200 million
or over is being targeted, but not confirmed by the firm.
Both the financial situation and business trends are not
determined due to the recent inception but should be good for MODERATE business
engagements. Max credit limit is
estimated at Yen 1 million for 30 days on basis of estimated turnover at Yen 50
million. Due to the absence and
non-disclosure of financials we recommend secured terms on new transactions.
REGISTRATION
Date Registered: Apr
2006
Legal Status: Limited
Company (Kabushiki Kaisha)
File No.: (Tokyo)
0199-01-103556
Authorized: 4
shares
Issued: 1
share
Sum: Yen
100 million
Major shareholders (%): Junzo
Ishiguro, others (--100)
No. of shareholders: 3
Nothing detrimental is known as to the commercial morality
of executives.
OPERATION
Activities: Technology transfer business in pharmaceuticals & biotechnology industries (100%), representing over 10 Western companies, such as:
Lectus Therapeutics, Scottish Biomedical, Xention, Senexis, Neuro Solutions (--UK), Onco Design (France), Qualia Clinical Services, Tandem Labs, Precision Med (--USA), other.
Business Partner: LSK Biopartners Inc (USA)
Clients: Pharmaceutical mfrs,
biomedical mfrs, other.
No. of accounts: Unavailable
Domestic areas of activities: Nationwide
Suppliers: [Pharmaceutical mfrs]
Over 10 Western companies as listed above.
Payment record: Regular
Location: Business area in Tokyo. Office premises at the caption address are leased and maintained
satisfactorily.
Bank References
Local Bank (Not disclosed)
Relations: Money deposits & transfers only
FINANCES
(In Million Yen)
NOT MADE AVAILABLE (NOT DISCLOSED)
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)